AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the release of an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: gastroAI-model G, registration number: 30500BZX00297000) on March 4, 2024. The endoscopic AI (hereinafter gastric cancer diagnosis support AI) assists the physician in diagnosis of neoplasia by detecting lesion candidates for biopsy[1] or other additional diagnostic steps based on gross visual features during endoscopy.

About gastric cancer diagnosis support AI “gastroAI-model G”

AIM has launched the gastric cancer diagnosis support AI, brand-named “gastroAI-model G,” with the manufacturing and marketing approval by Japan’s Minister of Health on December 26, 2023 (Registration number: 30500BZX00297000).

The software was developed based on training data provided by world-class medical institutions, utilizing deep learning technology and the support of more than 100 institutes for collaborative research.

The AI works by scanning for candidate lesions using a general-purpose computer, using images extracted from the endoscopy system’s video processor. When the program calculates that a lesion is suspicious for early gastric cancer and warrants further workup, it alerts the physician and provides diagnostic assistance by displaying a rectangle inside the endoscopic display area.

Product Information
Brand name: Endoscopic Diagnosis Support Software gastroAI-model G
Japanese Medical Device Nomenclature: Supporting software for detecting lesion with endoscopic imaging
Registration number: 30500BZX00297000

Product Website (for medical professionals):
https://www.gastroai.com/

Regarding sales of the device, AIM will provide the latest software at all times through annual subscription agreements. Aiming to improve the quality of endoscopic medical care in different settings, AIM will conduct product demonstrations not only at university hospitals and cancer centers but also at screening centers and endoscopy clinics.

AIM is committed to advancing our mission of “Save Lives All Over the World” through the use of endoscopic image diagnosis support AI.

About AI Medical Service Inc.

AI Medical Service (AIM) is a Tokyo-based med-tech company established with the mission to “Save Lives All Over the World.” Japan leads the world in endoscopic diagnosis and treatment, providing firms and researchers with access to large amounts of high-quality data. AIM is the leading player in the field of endoscopic AI, engaging in joint research with more than 100 medical institutions. By bringing endoscopic AI to the real-world clinical setting as soon as possible, AIM aims to reduce the number of missed cancer diagnoses and save lives around the world.

About CEO of AIM, Dr. Tomohiro Tada

Tomohiro TADA, M.D., Ph.D.

Dr. Tomohiro TADA is the CEO of AI Medical Service Inc., the chairperson of Tada Tomohiro The Institute of Gastroenterology & Proctology as well as Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, the University of Tokyo Hospital.

Dr. TADA received his M.D. of school of medicine in 1996 and Ph.D. of department of surgery in 2005 from the University of Tokyo. He trained in Colorectal Surgery at the University of Tokyo Hospital.

―――――――――――――――――――――――――――――

Company： AI Medical Service Inc.
Address： Hareza Tower 11F, 1-18-1 Higashiikebukuro, Toshima-ku, Tokyo 170-0013, Japan
CEO： Tomohiro Tada
Founding： September 1, 2017
Business： Development of Endoscopic AI

[1] “Biopsy” refers to taking a piece of tissue and examining it under a microscope when a lesion is found.

Back to list

Contact

Feel free to contact us using the form below regarding joint research,
media coverage, business partnerships, or related opportunities.